Biocon's Shaw Vows Insulin Commitment Despite Thin Margins

Founder Kiran Mazumdar-Shaw defends biosimilar insulin strategy on NDTV Profit, citing structural diabetes demand to counter analyst concerns over low-margin capital allocation.

ndtv-profit-business · 7/15/2026, 6:31:53 AM · Ask about this →